A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS (All monetary amounts are expressed in thousands of US dollars, unless stated otherwise) We are a global biotech company working to unlock the potential of cell and gene therapies (“CGTs”) in an affordable and accessible format. CGTs can be centered on autologous (using the patient’s own cells) or allogenic (using master banked donor cells) and are part of a class of medicines referred to as advanced therapy medicinal products (“ATMPs”). We are mostly focused on autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care (“POCare”).
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | -7.3M | - | 36M | 36M | 7.7M | - |
| Net Income | -62M | -55M | -15M | -18M | 1.1M | 24M |
| EPS | $18.66 | $19.10 | $5.90 | $7.40 | $-2.90 | $17.70 |
| Free Cash Flow | -16M | -17M | -37M | -35M | -80M | -25M |
| ROIC | -151.5% | -291.2% | -36.4% | -41.7% | 1.9% | 119.4% |
| Gross Margin | - | - | 85.8% | -3.2% | - | - |
| Debt/Equity | 0.00 | -0.94 | 0.49 | 0.13 | 0.14 | 2.37 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | - | $0.00 | - |
| Operating Income | -57M | -54M | -10M | -17M | -96M | 22M |
| Operating Margin | 0.0% | - | -28.1% | -47.3% | -1251.8% | - |
| ROE | 0.0% | -1683.2% | -54.0% | -46.9% | 2.1% | 440.4% |
| Shares Outstanding | 5M | 3M | 3M | 3M | 2M | 1M |
Orgenesis Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Orgenesis Inc. trades at 0.0x trailing earnings, compared to its 15-year median P/E of 3.6x, suggesting it is currently Cheap relative to its historical range. The company's 5-year average ROIC is 10.8% with a gross margin of 41.3%. At current prices, the estimated annualized return to fair value is -7.9%.
Orgenesis Inc. (ORGS) has a current P/E ratio of 0.0, compared to its historical median P/E of 3.6. The stock is currently considered Cheap based on its historical valuation range.
Orgenesis Inc. (ORGS) has a 5-year average return on invested capital (ROIC) of 10.8%. This indicates solid capital allocation.
Orgenesis Inc. (ORGS) has a market capitalization of $827K. It is classified as a small-cap stock.
Orgenesis Inc. (ORGS) does not currently pay a regular dividend.
Based on historical P/E analysis, Orgenesis Inc. (ORGS) appears cheap. The current P/E of 0.0 is 100% below its historical median of 3.6. The estimated fair value CAGR (P/E method) is -7.9%.
Orgenesis Inc. (ORGS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Orgenesis Inc. (ORGS) generated $-17 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Orgenesis Inc. (ORGS) reported earnings per share (EPS) of $19.10 in its most recent fiscal year.
Orgenesis Inc. (ORGS) has a return on equity (ROE) of -1683.2%. A negative ROE may indicate losses or negative equity.
Orgenesis Inc. (ORGS) has a 5-year average gross margin of 41.3%. This indicates decent pricing power.
The Ledger Terminal provides 12 years of financial data for Orgenesis Inc. (ORGS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Orgenesis Inc. (ORGS) has a book value per share of $-6.11, based on its most recent annual SEC filing.